Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Deficit)

v3.20.1
Stockholders' Equity (Deficit)
12 Months Ended
Dec. 31, 2019
Temporary Equity Disclosure [Abstract]  
Stockholders’ Equity (Deficit)

10. Stockholders’ Equity (Deficit)

 

Common Stock

Holders of common stock are entitled to one vote per share on all matters to be voted upon by the stockholders of the Company.

As of December 31, 2019 and 2018, the Company had reserved common stock, on an if-converted basis, for issuance as follows:

 

 

 

December 31,

 

 

 

2019

 

 

2018

 

Common stock options issued and outstanding

 

 

3,872,664

 

 

 

3,111,718

 

Common stock awards issued and outstanding

 

 

335,799

 

 

 

311,240

 

Remaining shares reserved for issuance under 2004

   and 2018 Equity Incentive Plan

 

 

2,750,416

 

 

 

2,525,610

 

Shares reserved for issuance under 2018 Employee

   Stock Purchase Plan

 

 

326,542

 

 

 

230,000

 

Warrants to purchase common stock

 

 

71,813

 

 

 

71,813

 

Total

 

 

7,357,234

 

 

 

6,250,381

 

 

Preferred Stock

 

Effective October 30, 2018, the Company had 10,000,000 shares of preferred stock authorized with a par value of $0.001. No shares of preferred stock were outstanding as of December 31, 2019 and 2018.

 

Warrants

During the period from 2008 to 2012, the Company issued various warrants for the purchase of redeemable convertible preferred stock in connection with debt financings and the issuance of redeemable convertible preferred stock.

In August 2017, the Company issued warrants to Oxford and SVB to purchase an aggregate of 682,230 shares of Series D-2 redeemable convertible preferred stock at an exercise price of $0.6596 per share in connection with the issuance of the August 2017 Loan. If there was a subsequent convertible preferred stock or other senior equity securities financing with a per share price less than the Series D-2 redeemable convertible preferred per share price, then the warrant would automatically convert to a warrant to purchase such class of shares, based on the per share price of such equity. Given that the price per share of the Series E redeemable convertible preferred stock described above was less than the price per share of the Series D-2 redeemable convertible preferred stock, the 2017 Warrant converted into a warrant to purchase a total of 1,682,871 shares of Series E redeemable convertible preferred stock at an exercise price of $0.2674 per share. The warrant is exercisable from the original date of issuance and has a 10-year term.

The Company adjusted the warrant liability for changes in fair value until the completion of its IPO on October 1, 2018, at which time certain convertible preferred stock warrants were converted into warrants for the purchase of common stock and the related convertible preferred stock warrant liability was reclassified to additional paid-in capital and others expired.  On October 1, 2018, 1,232,220 shares of the Series C redeemable convertible preferred warrants were canceled, and the remaining 687,928 shares were converted to 25,454 shares of warrants to purchase common stock on a 1-for-0.0370 basis. All Series E redeemable convertible preferred warrants were converted to 46,359 shares of warrants to purchase common stock on a 1-for-0.0275 basis.